Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma

被引：4

作者：

Friedberg J.W. ^{[1
]}

Freedman A.S. ^{[1
]}

机构：

[1] James P. Wilmot Cancer Center, University of Rochester, Rochester, NY 14642

来源：

Current Treatment Options in Oncology | 2006年 / 7卷 / 4期

关键词：

Follicular Lymphoma; Immunomodulatory Agent; Indolent Lymphoma; Monoclonal Antibody Therapy; Combination Immunotherapy;

D O I：

10.1007/s11864-006-0037-2

中图分类号：

学科分类号：

摘要：

Immunomodulatory agents, including cytokines, monoclonal antibodies, and CpG oligonucleotides, have properties that suggest they have the ability to augment rituximab in the treatment of non-Hodgkin's lymphoma. Although several clinical trials have promising results, no randomized trials of reasonable size have been performed to date, limiting the ability to discern whether combinations of immunomodulatory agents with rituximab impact clinical outcome. Until such trials are mature, we do not recommend using these agents in combination outside of the research setting. Copyright © 2006 by Current Science Inc.

引用

页码：276 / 284

页数：8

共 39 条

[1]

Nadler L.M., Stashenko P., Hardy R., Et al., Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen, Cancer Res, 40, pp. 3147-3154, (1980)

[2]

McLaughlin P., Grillo-Lopez A.J., Link B.K., Et al., Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program, J Clin Oncol, 16, pp. 2825-2833, (1998)

[3]

Ghielmini M., Schmitz S.F., Cogliatti S.B., Et al., Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule, Blood, 103, pp. 4416-4423, (2004)

[4]

Ghielmini M., Multimodality therapies and optimal schedule of antibodies: Rituximab in lymphoma as an example, Hematology (Am Soc Hematol Educ Program), pp. 321-328, (2005)

[5]

Gordon L.I., Solal-Celigny P., Gascoyne R.D., Freedman A.S., Follicular lymphoma: Management options in the era of targeted therapy, ASCO Educational Book, pp. 511-526, (2005)

[6]

Friedberg J.W., Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy, Hematology (Am Soc Hematol Educ Program), pp. 329-334, (2005)

[7]

Smith M.R., Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance, Oncogene, 22, pp. 7359-7368, (2003)

[8]

Uchida J., Hamaguchi Y., Oliver J.A., Et al., The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy, J Exp Med, 199, pp. 1659-1669, (2004)

[9]

Cartron G., Dacheux L., Salles G., Et al., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene, Blood, 99, pp. 754-758, (2002)

[10]

Ghielmini M., Rufibach K., Salles G., Et al., Single agent rituximab in patients with follicular or mantle cell lymphoma: Clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: A study of the Swiss Group for Clinical Cancer Research (SAKK), Ann Oncol, 16, pp. 1675-1682, (2005)

← 1 2 3 4 →